Bicycle Therapeutics (BCYC) Projected to Post Quarterly Earnings on Thursday

Bicycle Therapeutics (NASDAQ:BCYC) is projected to announce its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of ($1.05) per share for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 6, 2025 at 6:00 AM ET.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Friday, August 8th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.19). Bicycle Therapeutics had a negative net margin of 1,257.00% and a negative return on equity of 32.43%. The business had revenue of $2.90 million during the quarter, compared to analysts’ expectations of $9.43 million. On average, analysts expect Bicycle Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Bicycle Therapeutics Price Performance

NASDAQ BCYC opened at $8.12 on Tuesday. Bicycle Therapeutics has a 1 year low of $6.10 and a 1 year high of $25.66. The company has a market capitalization of $562.80 million, a PE ratio of -2.31 and a beta of 1.47. The company has a fifty day moving average of $7.56 and a two-hundred day moving average of $7.84.

Insider Buying and Selling

In related news, CEO Kevin Lee sold 3,231 shares of the firm’s stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $8.41, for a total value of $27,172.71. Following the completion of the sale, the chief executive officer owned 475,310 shares in the company, valued at $3,997,357.10. This trade represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 8,527 shares of company stock valued at $71,738 in the last three months. 8.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. State of Tennessee Department of Treasury acquired a new stake in Bicycle Therapeutics in the second quarter valued at about $100,000. Soleus Capital Management L.P. purchased a new position in Bicycle Therapeutics in the second quarter valued at about $695,000. Monimus Capital Management LP purchased a new position in Bicycle Therapeutics in the second quarter valued at about $592,000. Rangeley Capital LLC purchased a new position in Bicycle Therapeutics in the second quarter valued at about $521,000. Finally, Moore Capital Management LP increased its holdings in Bicycle Therapeutics by 50.0% in the second quarter. Moore Capital Management LP now owns 75,000 shares of the company’s stock valued at $521,000 after buying an additional 25,000 shares in the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Bicycle Therapeutics in a research note on Tuesday, October 14th. JMP Securities decreased their target price on shares of Bicycle Therapeutics from $22.00 to $10.00 and set a “market outperform” rating for the company in a research note on Tuesday, August 12th. Morgan Stanley decreased their target price on shares of Bicycle Therapeutics from $17.00 to $13.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 12th. Oppenheimer reiterated an “outperform” rating and set a $44.00 target price (down previously from $48.00) on shares of Bicycle Therapeutics in a research note on Monday, August 11th. Finally, Royal Bank Of Canada set a $27.00 target price on shares of Bicycle Therapeutics and gave the stock an “outperform” rating in a research note on Monday, August 11th. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bicycle Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $22.22.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.